Last reviewed · How we verify

NCT03057158: GENIE

Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study

Completed Last updated 29 September 2020
What this trial tests

trial in Overactive Bladder in 257 participants. Completed in 11 March 2020.

Timeline
1 May 2017
Primary endpoint
9 March 2020
11 March 2020

Quick facts

Lead sponsorDuke University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment257
Start date1 May 2017
Primary completion9 March 2020
Estimated completion11 March 2020
Sites1 location across United States

Conditions studied

Sponsor

Duke University

Who can join

18 and older, female only, with Overactive Bladder or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Millions of women suffer from overactive bladder, and the changes in bladder function affect their quality of life. The study team believes that it needs to be better understand why women get overactive bladder in the first place so that better treatments can eventually be offered. The purpose of this study is to determine why women with insulin resistance are more likely to get overactive bladder. Overactive bladder is a type of bladder control problem that can cause some women to have bladder leakage. This problem is more common in women with diabetes and pre-diabetes, but it isn't known why.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03057158.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing